Crown Bioscience January 2023 Newsletter

Welcome to the monthly Crown Bioscience newsletter. Discover some of our January highlights below to keep up to date with our recent developments, and to learn more about our services. Don't forget to follow us on LinkedIn to avoid missing our daily updates!

This new study reports on the largest living, commercially available PDXO biobank—with approximately 550 tumor organoid models derived from a collection of matched PDXs representing 17 different types of carcinomas.

We have launched our new discovery proteomics services using ion mobility (IM) mass spectrometry. This combines IM separation with data independent acquisition strategy in LC-MS, enabling an accurate and comprehensive analysis of your complex biological samples.

Examine how enhancing the predictivity of cancer drug discovery with 3D?in vitro?organoids, as opposed to traditional 2D monolayer culture systems, more closely recapitulates the complex?in vivo?environment. Using these organoids enables "clinical trials in a dish," which can improve and accelerate cancer drug discovery.

Discover a unique high content screening platform for Autosomal Dominant Polycystic Kidney Disease and 3D cyst swelling assay for Cystic Fibrosis. Our unique high content screening platforms enables the recapitulation of the?in vivo?disease phenotype with robust functional readouts.

Our Tech Talk series provides an introduction to?in vivo?oncology and I/O models, strategies, and tools. In under 20 minutes each, watch any of the tech talks in the series on-demand to discover which?in vivo?models, platforms, and technologies can best support your preclinical oncology studies.

A 3D High Content Imaging (HCI) assay for immuno-oncology drugs using patient tumors with the preserved native tumor microenvironment. Explore how this service can help you evaluate drug responses in patient tumors with the endogenous immune cell population intact.

In this on-demand webinar, we use case studies to demonstrate how to identify potential biomarkers at the preclinical study stage through better experimental design, comprehensive biomarker analysis, and powerful bioinformatics data analysis.

? 2023?Crown Bioscience, Inc.

Crown Bioscience, Inc.16550 West Bernardo Drive, Building 5, Suite 525, San Diego, CA 92127, United States